1. Universidad Nacional de Córdoba, Argentina (F.M.).
2. BHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
3. Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy (M. Serenelli).
4. Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (J.C.N.).
5. General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan (C.E.-C.).
6. Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology of Russia, Moscow (S.T.).
7. Division of Cardiovascular Medicine (S.D.S.), Brigham and Women’s Hospital, Boston, MA.
8. Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
9. Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Denmark (L.K.).
10. Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City (M.N.K.).
11. The George Institute for Global Health, University of New South Wales, Sydney, Australia (M.N.K.).
12. Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
13. TIMI Study Group (M.S.S.), Brigham and Women’s Hospital, Boston, MA.
14. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).
15. Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland (M.D.-P.).
16. Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).